RxDoctor Payments Data

Gina Tundo, MD

Urogynecology and Reconstructive Pelvic Surgery · Cheektowaga, NYNPI 1003293887

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 41 payments — averaging $30.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$414
  • Astellas Pharma US Inc$155
  • Calyxo, Inc.$133
  • Innovation Technologies Inc$101
  • Sumitomo Pharma America, Inc.$101
  • Laborie Medical Technologies Corp.$70
  • plus $261 from 11 others

What the payments were for

  • Food & beverage$1,07987%
  • Education$15613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 25th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.

See all urogynecology and reconstructive pelvic surgery providers in New York

Medicare billing

Part B allowed, 2024
$103,020
Medicare patients
360
Services billed
1,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron174$137,623
GemtesaVibegron84$91,440
Mirabegron ErMirabegron12$9,383
Trospium Chloride ErTrospium Chloride42$8,522
Estradiol92$7,012
Tamsulosin Hcl78$1,122
Solifenacin Succinate19$1,035
Tolterodine Tartrate ErTolterodine Tartrate12$752
Cefdinir59$536
Cephalexin55$518
Tadalafil11$451
Amitriptyline Hcl21$280
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim40$123
Ciprofloxacin Hcl22$97
Fluconazole13$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$155$137,623174 claims
Sumitomo Pharma America, Inc.Gemtesa$101$91,44084 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.

Other urogynecology and reconstructive pelvic surgery in Cheektowaga

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →